ImmunoPrecise Antibodies Ltd News - IPA

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic...

IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television Canada NewsWire VICTORIA, BC, Oct...

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends Canada...

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021 Canada NewsWire VICTORIA, BC...

IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television

IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television Canada NewsWire VICTORIA, BC, Sept. 28, 2020 VICTORIA, BC, Sept. 28, 2020...

ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day

ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day Canada NewsWire VICTORIA, BC, Sept...

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials Canada NewsWire VICTORIA, BC, Sept...

IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select ™

IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select...

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks Canada...

ImmunoPrecise Commences Application Process to Dual List on NASDAQ

ImmunoPrecise Commences Application Process to Dual List on NASDAQ Canada NewsWire VICTORIA, BC, Sept. 10...

ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 202...

ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IPA News

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test

IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021

IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television

ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select ™

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

ImmunoPrecise Commences Application Process to Dual List on NASDAQ

ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 202...

IPA CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

ImmunoPrecise Antibodies Grants Stock Options

ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020

IPA Appoints New York Based Crescendo Communications as Investor Relations and Corporate Communications Advisor

IPA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA) News

ImmunoPrecise Antibodies Ltd (IPA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IPA News

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test

IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021

IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg Television

ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor Day

ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select ™

ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

ImmunoPrecise Commences Application Process to Dual List on NASDAQ

ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 202...

IPA CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

ImmunoPrecise Antibodies Grants Stock Options

ImmunoPrecise Reports Record Revenues and Positive Adjusted EBITDA Fiscal 2020

IPA Appoints New York Based Crescendo Communications as Investor Relations and Corporate Communications Advisor

IPA Discussion

Your Recent History